[O6] Oral Session 6　Lung Cancer / Thoracic Cancer 1（Molecularly-targeted therapy EGFR, ALK）
【E】

[O6-1] Randomized phase II study of osimertinib+bevacizumab vs. osimertinib for untreated patients with EGFR+non-squamous NSCLC

^○Terufumi Kato¹, Hirotsugu Kenmotsu², Kazushige Wakuda², Keita Mori³, Shunichi Sugawara⁴, Keisuke Kirita⁵, Isamu Okamoto⁶, Koichi Azuma⁷, Kazumi Nishino⁸, Shunsuke Teraoka⁹, Ryo Koyama¹⁰, Ken Masuda¹¹, Hidetoshi Hayashi¹², Ryo Toyozawa¹³, Satoru Miura¹⁴, Yuki Sato¹⁵, Kazuhiko Nakagawa¹², Nobuyuki Yamamoto⁹, Toshiaki Takahashi² (1.Department of Thoracic Oncology, Kanagawa Cancer Center, 2.Division of Thoracic Oncology, Shizuoka Cancer Center, 3.Clinical Research Support Center, Shizuoka Cancer Center, 4.Department of Pulmonary Medicine, Sendai Kousei Hospital, 5.Department of Thoracic Oncology, National Cancer Center Hospital East, 6.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 7.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 8.Department of Thoracic Oncology, Osaka International Cancer Institute, 9.Internal Medicine III, Wakayama Medical University, 10.Department of Respiratory Medicine, Juntendo University, 11.Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, 12.Department of Medical Oncology, Faculty of Medicine, Kindai University, 13.Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 14.Department of Internal Medicine, Niigata Cancer Center Hospital, 15.Department of Respiratory Medicine, Kobe City Medical Center General Hospital)